The listing of claims will replace all prior versions, and listings of claims in the application:

Listing of claims:

1. (Currently Amended) A compound of Formula I:



in which:

n is 0, 1 or 2;

R_1 is chosen from $C_{6\text{-}10}$aryl ~~and $C_{5\text{-}10}$heteroaryl; wherein any aryl or heteroaryl of R_1 is~~ optionally substituted by a ~~radical chosen from $C_{6\text{-}10}$aryl$C_{0\text{-}4}$alkyl, $C_{5\text{-}6}$heteroaryl$C_{0\text{-}4}$alkyl,~~ $C_{3\text{-}8}$cycloalkyl~~$C_{0\text{-}4}$alkyl, $C_{3\text{-}8}$heterocycloalkyl$C_{0\text{-}4}$alkyl or $C_{1\text{-}10}$alkyl~~; wherein any aryl~~, heteroaryl,~~ or cycloalkyl ~~or heterocycloalkyl~~ group of R_1 can be optionally substituted by one to five radicals selected from the group consisting of halo, $C_{1\text{-}10}$alkyl, $C_{1\text{-}10}$alkoxy, halo-substituted-$C_{1\text{-}10}$alkyl and halo-substituted-$C_{1\text{-}10}$alkoxy; ~~and any alkyl group of R_1 can optionally have a methylene replaced by an atom or group chosen from –S–, –S(O)–, –S(O)$_2$–, –NR$_4$– and –O–; wherein R_4 is chosen from hydrogen or $C_{1\text{-}6}$alkyl;~~

R_2 and R_3 are independently chosen from hydrogen, $C_{1\text{-}6}$alkyl, halo, hydroxy, $C_{1\text{-}6}$alkoxy, halo-substituted $C_{1\text{-}6}$alkyl and halo-substituted $C_{1\text{-}6}$alkoxy;

A is ~~chosen from~~ –X_1C(O)OR_4~~, –X_1OP(O)(OR_4)$_2$, –X_1P(O)(OR_4)$_2$, –X_1P(O)OR_4, –X_1S(O)$_2$OR_4, –X_1P(O)(R_4)OR_4 and 1*H*-tetrazol-5-yl;~~ wherein X_1 is a bond or $C_{1\text{-}6}$alkylene and R_4 is chosen from hydrogen and $C_{1\text{-}6}$alkyl;

W is methylene ~~chosen from a bond, $C_{1\text{-}6}$alkylene and $C_{2\text{-}6}$alkenylene~~;

X is ~~chosen from $C_{2\text{-}4}$alkylene and~~ $C_{2\text{-}4}$alkenylene; wherein one methylene group of X can be replaced with an –O– atom ~~or group chosen from –O–, –S–, –S(O)–, –S(O)$_2$– and –NR$_5$–; wherein R_5 is hydrogen, $C_{1\text{-}6}$alkyl and –C(O)R_6; wherein R_6 is chosen from hydrogen and $C_{1\text{-}6}$alkyl; wherein any alkylene or alkenylene of X can further be substituted by 1 to 3 radicals selected from the group consisting of halo, hydroxy, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, halo-substituted $C_{1\text{-}10}$alkyl and halo-substituted $C_{1\text{-}10}$alkoxy~~;

Y is chosen from C_{6-10}aryl and C_{5-10}heteroaryl, wherein any aryl or heteroaryl of Y can be optionally substituted with 1 to 3 radicals chosen from halo, hydoxy, nitro, C_{1-10}alkyl, C_{1-10}alkoxy, halo-substituted C_{1-10}alkyl and halo-substituted C_{1-10}alkoxy;

Z is C_{1-6}alkylene; wherein up to two methylene groups of Z can be replaced with divalent radicals chosen from $-NR_7-$, C_{3-8}cycloalkylene, C_{3-8}heterocycloalkylene and phenylene; wherein R_7 is chosen from hydrogen, C_{1-6}alkyl and $(CH_2)_{1-2}COOH$; wherein Z may further be substituted by 1 to 3 radicals chosen from halo, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substitued-C_{1-6}alkyl and halo-substitued-C_{1-6}alkoxy; or when a $-NR_7-$ replaces at least one methylene group of Z, R_7 and Y together with the nitrogen atom to which R_7 is attached, forms C_{8-14}heteroarylene; and the pharmaceutically acceptable salts~~, hydrates, solvates, isomers and prodrugs~~ thereof.

2. (Currently Amended) The compound of claim 2 in which n is 0 or 1 and Z is chosen from:





wherein the left and right asterisks of Z indicate the point of attachment between the –$[C(R_2)(R_3)]_n$– group and A of Formula I, respectively; R_7 is chosen from hydrogen and C_{1-6}alkyl~~;~~ ~~and J_1, J_2 and J_3 are independently methylene or a heteroatom selected from the group consisting of S, O and NR_4; wherein R_4 is hydrogen or C_{1-6}alkyl; with the proviso that the number of heteroatoms are 2 or less~~.

3. (Currently Amended) The compound of claim 1 in which R_1 is chosen from phenyl~~,~~ ~~naphthyl and thiophenyl~~ optionally substituted by ~~C_{6-10}arylC_{0-4}alkyl, C_{5-6}heteroarylC_{0-4}alkyl,~~ C_{3-8}cycloalkyl~~C_{0-4}alkyl, C_{3-8}heterocycloalkylC_{0-4}alkyl or C_{1-10}alkyl~~; wherein any aryl~~, heteroaryl,~~ or cycloalkyl ~~or heterocycloalkyl~~ group of R_1 can be optionally substituted by 1 to 5 radicals chosen from halo, C_{1-10}alkyl, ~~C_{1-10}alkoxy,~~ and halo-substituted-C_{1-10}alkyl ~~and halo-substituted C_{1-10}alkoxy; and any alkyl group of R_4 can optionally have a methylene replaced by an atom or group chosen from –S–, –S(O)–, –S(O)$_2$–, –NR_4– and –O–; wherein R_4 is hydrogen or C_{1-6}alkyl~~.

4. (Currently Amended) The compound of claim 1 in which Y is chosen from phenyl, pyridine, pyrimidine, thiophene, furan, thiazole and oxazole; each of which can be optionally substituted with 1 to 3 radicals chosen from halo, hydoxy, nitro, C_{1-10}alkyl, C_{1-10}alkoxy, halo-substituted C_{1-10}alkyl and halo-substituted C_{1-10}alkoxy.

5. (Currently Amended) The compound of claim 1 in which R_2 and R_3 are both hydrogen and A is ~~chosen from~~ –C(O)OR_4 ~~and 1*H*-tetrazol-5-yl~~; wherein R_4 is ~~chosen from~~ hydrogen ~~and C_{1-6}alkyl~~.

6. (Currently Amended) The compound of claim 1 in which R_1 is ~~chosen from~~:



wherein the asterisk is the point of attachment of R_1 with W; R_9 is ~~C_{6-10}arylC_{0-4}alkyl, C_{5-6}heteroarylC_{0-4}alkyl,~~ C_{3-8}cycloalkyl~~C_{0-4}alkyl, C_{3-8}heterocycloalkylC_{0-4}alkyl or C_{1-10}alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R_9 can be optionally substituted by 1 to 3 radicals chosen from halo, C_{1-10}alkyl, C_{1-10}alkoxy, halo-substituted-C_{1-10}alkyl and halo-substituted-C_{1-10}alkoxy; and any alkyl group of R_9 can optionally have a methylene replaced by an atom or group chosen from -S-, -S(O)-, -$S(O)_2$-, -NR_4- and -O-; wherein R_4 is hydrogen or C_{1-6}alkyl~~; and R_{10} is selected from ~~halo,~~ C_{1-10}alkyl, ~~C_{1-10}alkoxy,~~ and halo-substituted-C_{1-10}alkyl ~~and halo-substituted-C_{1-10}alkoxy~~.

7. (Original) The compound of claim 1 chosen from: 3-{[5-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl]-amino}-propionic acid; 1-[5-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl]-azetidine-3-carboxylic acid; 3-{[6-chloro-4-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-chroman-7-ylmethyl]-amino}-propionic acid; 3-{[3-chloro-5-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl]-amino}-propionic acid; 1-[3-Chloro-5-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl]-azetidine-3-carboxylic acid; 1-[5-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-3-methoxy-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl]-azetidine-3-carboxylic acid; 3-{[5-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-3-methoxy-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl]-amino}-propionic acid; 3-{[8-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-5,6,7,8-tetrahydro-quinolin-3-ylmethyl]-amino}-propionic acid; 1-[8-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-5,6,7,8-tetrahydro-quinolin-3-ylmethyl]-azetidine-3-carboxylic acid; 3-{4-[5-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-5,6,7,8-tetrahydro-naphthalen-2-yl]-piperazin-1-yl}-propionic acid; 3-{[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-indan-5-ylmethyl]-amino}-propionic acid; 1-[8-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl]-azetidine-3-carboxylic acid; 3-{[8-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl]-amino}-propionic acid; 3-{[5-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-3-ethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl]-amino}-propionic acid; 3-{[4-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-chroman-6-ylmethyl]-amino}-propionic acid; 3-{[4-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-chroman-7-ylmethyl]-amino}-

propionic acid; 1-[4-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-chroman-7-ylmethyl]-azetidine-3-carboxylic acid; 3-{[4-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-3,4-dihydro-2H-pyrano[2,3-b]pyridin-7-ylmethyl]-amino}-propionic acid; 1-[4-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-3,4-dihydro-2H-pyrano[2,3-b]pyridin-7-ylmethyl]-azetidine-3-carboxylic acid; 1-[4-(4-cyclohexyl-3-methyl-benzyloxyimino)-chroman-7-ylmethyl]-azetidine-3-carboxylic acid; and 3-{[4-(4-cyclohexyl-3-methyl-benzyloxyimino)-chroman-7-ylmethyl]-amino}-propionic acid.

8. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.

9. (Currently Amended) A method for treating a disease in ~~a an animal~~ human in which alteration of EDG/S1P receptor mediated signal transduction can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1.

10. (Currently Amended) A method for preventing or treating ~~disorders or diseases mediated by lymphocytes, for treating~~ breast cancer, acute or chronic transplant rejection ~~or T-cell mediated inflammatory or autoimmune diseases, for inhibiting~~ or controlling deregulated angiogenesis~~, or for treating diseases mediated by a neo-angiogenesis process or associated with deregulated angiogenesis~~ in a subject comprising administering to the subject in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

11. (Canceled).

12. (Canceled).

.